Dr. Cooper focuses on developing novel therapies for acute myeloid leukemia (AML), which has an approximately 50% mortality rate. Her work focuses on C/EBPalpha, a protein that is decreased in more than half of all AML patients. By determining how the production of this protein is regulated, she aims to understand the mechanisms for its reduction in leukemia and to develop strategies to target C/EBPalpha as a novel therapy for AML.
Damon Runyon Researchers
Meet Our Scientists
Stacy L. Cooper, MD
Project title: "The Cebpa +37kb enhancer is a critical target of transformation in acute myeloid leukemia"
Institution: The Johns Hopkins University
Award Program: Sohn Fellow
Sponsor(s) / Mentor(s): Alan D. Friedman, MD
Cancer Type: Blood, Pediatric
Research Area: Epigenetics
